---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-043393"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-12-01T23:59:59+00:00"
generated_at: "2026-06-07T19:26:26.649921+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AgeX Therapeutics COO to depart as Juvenescence terminates services agreement; $3.9M debt

## Summary
- Juvenescence notified AgeX it is terminating the agreement that provided Nafees Malik as COO; termination effective Dec 31, 2023.
- Dr. Malik's engagement as COO of AgeX and its subsidiary Reverse Bioengineering ends December 27, 2023.
- As of Nov 27, 2023, AgeX owed Juvenescence $3.9 million in secured loans and fees.
- Juvenescence, AgeX's largest shareholder (79.4% of outstanding common shares), provided Dr. Malik's services at 85% cost.
- No replacement for COO has been announced.

## SEC filing metadata
- accession: 0001493152-23-043393
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-12-01T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/0001493152-23-043393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-043393
- JSON: https://secwatch.observer/filing/0001493152-23-043393.json
- Plain text: https://secwatch.observer/filing/0001493152-23-043393.txt

## Key facts
- Executive change
  Nafees Malik departed as Chief Operating Officer at Serina Therapeutics, Inc..
  - Role: Chief Operating Officer
  source text: In connection with the termination of the agreement pursuant to which Juvenescence has provided the services of our Chief Operating Officer, Nafees Malik, as set forth in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/0001493152-23-043393-index.htm
- Material Agreements
  Serina Therapeutics, Inc. terminated Service Agreement with Juvenescence Limited for Dr. Nafees Malik with Juvenescence Limited valued at Termination of agreement for Dr. Malik's services; AgeX paid Juvenescence 85% of Dr. Malik's base sa (effective 2023-12-31).
  - Action: termination
  - Counterparty: Juvenescence Limited
  - Value: Termination of agreement for Dr. Malik's services; AgeX paid Juvenescence 85% of Dr. Malik's base sa
  - Effective: 2023-12-31
  source text: On November 27, 2023, Juvenescence Limited (“Juvenescence”) notified AgeX that Juvenescence is terminating a March 29, 20219 the agreement that incorporated arrangements in effect since October 18, 2018 pursuant to which Juvenescence has provided AgeX with the services of Juvenescence’s employee Nafees Malik who served as Chief Operating Officer of AgeX and our subsidiary Reverse Bioengineering, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/0001493152-23-043393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.